CA2573138A1 - Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors - Google Patents
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors Download PDFInfo
- Publication number
- CA2573138A1 CA2573138A1 CA002573138A CA2573138A CA2573138A1 CA 2573138 A1 CA2573138 A1 CA 2573138A1 CA 002573138 A CA002573138 A CA 002573138A CA 2573138 A CA2573138 A CA 2573138A CA 2573138 A1 CA2573138 A1 CA 2573138A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- alkyl
- butyl
- independently selected
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/84—Hydrazones having doubly-bound carbon atoms of hydrazone groups being part of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58620704P | 2004-07-09 | 2004-07-09 | |
US60/586,207 | 2004-07-09 | ||
US60814304P | 2004-09-09 | 2004-09-09 | |
US60/608,143 | 2004-09-09 | ||
US65687305P | 2005-03-01 | 2005-03-01 | |
US60/656,873 | 2005-03-01 | ||
US68113805P | 2005-05-16 | 2005-05-16 | |
US60/681,138 | 2005-05-16 | ||
PCT/US2005/024469 WO2006010095A2 (en) | 2004-07-09 | 2005-07-11 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2573138A1 true CA2573138A1 (en) | 2006-01-26 |
Family
ID=35462378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002573138A Abandoned CA2573138A1 (en) | 2004-07-09 | 2005-07-11 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
Country Status (5)
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI332943B (en) * | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
CA2572775A1 (en) * | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals, Inc. | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
JP2009511589A (ja) * | 2005-10-12 | 2009-03-19 | エラン ファーマシューティカルズ,インコーポレイテッド | アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法 |
CA2660524A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceutical Corp. | Compounds for treating proliferative disorders |
WO2012076165A1 (en) | 2010-12-08 | 2012-06-14 | Grünenthal GmbH | Method for synthesising substituted aminocyclohexanone derivatives |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4835164A (en) | 1987-02-20 | 1989-05-30 | A. H. Robins Company, Incorporated | Aryloxymethyl derivatives of nitrogenous heterocyclic methanols and ethers thereof |
DE4004820A1 (de) * | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
US5912410A (en) * | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
JPH06507782A (ja) * | 1990-06-15 | 1994-09-08 | サイオス ノバ インコーポレイテッド | アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物 |
ATE447016T1 (de) * | 1991-01-21 | 2009-11-15 | Elan Pharm Inc | Prüfung und modell für alzheimers-krankheit |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
ES2204899T3 (es) * | 1992-01-07 | 2004-05-01 | Elan Pharmaceuticals, Inc. | Modelos de animales transgenicos para la enfermedad de alzheimer. |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
EP0727419B1 (en) * | 1992-12-29 | 2002-02-27 | Abbott Laboratories | Intermediates for the preparation of retroviral protease inhibiting compounds |
DE1001019T1 (de) * | 1993-10-27 | 2001-01-11 | Lilly Co Eli | Transgene Tiere, die APP Allele mit der schwedischen Mutation beherbergen |
US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
AU6383396A (en) * | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
CA2271294A1 (en) | 1996-11-20 | 1998-05-28 | Oklahoma Medical Research Foundation | Cloning and characterization of napsin, an aspartic protease |
US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
GB9812189D0 (en) | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
DK1115874T3 (da) | 1998-09-24 | 2009-04-20 | Pharmacia & Upjohn Co Llc | Alzheimer's sygdom-sekretase |
CN1390232A (zh) | 1999-02-10 | 2003-01-08 | 艾兰制药公司 | 人β分泌酶、抑制剂、其组合物和用途 |
US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
JP2003523944A (ja) | 1999-08-09 | 2003-08-12 | ヴァンダービルト ユニヴァースティ | P−糖タンパク質修飾物質を用いる抗ウィルス療法 |
ATE431419T1 (de) | 1999-09-23 | 2009-05-15 | Pharmacia & Upjohn Co Llc | Alzheimer krankheit sekretase, app (amyloid vorlaüfer-protein) substrate dafür und verwendungen |
PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
US7067550B2 (en) * | 2000-11-03 | 2006-06-27 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's Disease |
AR035960A1 (es) | 2001-04-23 | 2004-07-28 | Elan Pharm Inc | Epoxidos sustituidos y procesos para prepararlos |
CA2448834A1 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases |
US7361688B2 (en) | 2001-06-11 | 2008-04-22 | Elan Pharmaceuticals, Inc. | Substituted aminoalcohols useful in treatment of Alzheimer's disease |
JP2005505506A (ja) | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
US6864290B2 (en) | 2001-07-10 | 2005-03-08 | Pharmacia & Upjohn, Llp | Statine derivatives for the treatment of Alzheimer's disease |
OA12698A (en) | 2001-07-11 | 2006-06-22 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl)substituted alkylamidecompounds. |
MXPA04003245A (es) | 2001-10-04 | 2004-08-11 | Elan Pharm Inc | Hidroxipropilaminas. |
CA2466284A1 (en) * | 2001-11-08 | 2003-05-15 | Elan Pharmaceuticals, Inc. | N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
JP2005511735A (ja) * | 2001-12-06 | 2005-04-28 | イーラン ファーマスーティカルズ、インコーポレイテッド | 置換ヒドロキシエチルアミン |
KR20050032025A (ko) * | 2002-02-27 | 2005-04-06 | 엘란 파마슈티칼스, 인크. | 치환된 히드록시에틸아민 |
UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
JP2006501282A (ja) * | 2002-09-27 | 2006-01-12 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための化合物 |
US7109217B2 (en) | 2002-11-12 | 2006-09-19 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease |
CA2507484A1 (en) | 2002-11-27 | 2004-06-17 | Elan Pharmaceuticals, Inc. | Substituted ureas and carbamates |
GB0228410D0 (en) * | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
CL2004000848A1 (es) | 2003-04-21 | 2005-01-28 | Elan Pharmaceuticals Inc Pharm | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras |
WO2004094384A2 (en) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease |
GB0317491D0 (en) | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
US7598250B2 (en) | 2003-08-08 | 2009-10-06 | Schering Corporation | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent |
EP1660443B1 (en) | 2003-08-08 | 2009-03-04 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
US20060014737A1 (en) * | 2004-03-09 | 2006-01-19 | Varghese John | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors |
US20050239836A1 (en) * | 2004-03-09 | 2005-10-27 | Varghese John | Substituted hydroxyethylamine aspartyl protease inhibitors |
EP1735293A2 (en) * | 2004-03-09 | 2006-12-27 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
JP2007528403A (ja) | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ,インコーポレイテッド | 二環式アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
JP2007533740A (ja) | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Bace阻害剤としてのアミド |
CA2572775A1 (en) * | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals, Inc. | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
-
2005
- 2005-07-11 EP EP05773727A patent/EP1773756A2/en not_active Withdrawn
- 2005-07-11 JP JP2007520579A patent/JP2008505930A/ja active Pending
- 2005-07-11 US US11/177,324 patent/US7385085B2/en not_active Expired - Fee Related
- 2005-07-11 WO PCT/US2005/024469 patent/WO2006010095A2/en active Application Filing
- 2005-07-11 CA CA002573138A patent/CA2573138A1/en not_active Abandoned
-
2008
- 2008-05-08 US US12/117,094 patent/US20090042961A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006010095A3 (en) | 2006-06-08 |
US20090042961A1 (en) | 2009-02-12 |
EP1773756A2 (en) | 2007-04-18 |
US7385085B2 (en) | 2008-06-10 |
JP2008505930A (ja) | 2008-02-28 |
US20070149584A9 (en) | 2007-06-28 |
WO2006010095A2 (en) | 2006-01-26 |
US20060135581A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7858642B2 (en) | Substituted hydroxyethylamine aspartyl protease inhibitors | |
US20050239790A1 (en) | Substituted hydroxyethylamine aspartyl protease inhibitors | |
US20050239832A1 (en) | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | |
US20060014737A1 (en) | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | |
US20060014790A1 (en) | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | |
US20070149525A1 (en) | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | |
US20050261273A1 (en) | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | |
US20090042961A1 (en) | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | |
US7906556B2 (en) | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | |
US20060128715A1 (en) | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | |
US20080166332A1 (en) | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | |
US20060074098A1 (en) | Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |